Distant Disease‑Free Survival Is a Reliable Surrogate for Overall Survival in Most Neoadjuvant Early Breast Cancer Trials — but Not All Subtypes
Highlights
– A pooled individual‑patient analysis of 11 GBG and AGO‑B randomized neoadjuvant trials (15 comparisons, 12,247 patients) shows strong trial‑level surrogacy of distant disease‑free survival (DDFS) for overall survival (OS) (R2trial = 0.91; 95% CI 0.82–1.00).
– Surrogacy was consistent across most clinical subgroups but varied by molecular subtype: strong in HR‑/HER2‑ and HR‑/HER2+ tumours, weak in HR+/HER2‑ and HR+/HER2+ tumours.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.